Volume 13 Issue 3
May  2022
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2022  >  13(3): 288-295
Zhou Aiwei, Liu Yuan, Xue Feng, et al. Research progress on immune tolerance after pediatric liver transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(3): 288-295. doi: 10.3969/j.issn.1674-7445.2022.03.002
Citation: Zhou Aiwei, Liu Yuan, Xue Feng, et al. Research progress on immune tolerance after pediatric liver transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(3): 288-295. doi: 10.3969/j.issn.1674-7445.2022.03.002
shu

Research progress on immune tolerance after pediatric liver transplantation

doi: 10.3969/j.issn.1674-7445.2022.03.002

  • Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

More Information
  • Corresponding author: Xue Feng, Email: fengxue6879@163.com
  • Received Date: 2022-01-18
    Available Online: 2022-04-29
  • Publish Date: 2022-05-15
    Abstract
  • Immune tolerance after liver transplantation refers to discontinuing use of immunosuppressants in varying patterns and maintaining the long-term stability of liver function of the recipients. At present, immune tolerance may be achieved by passive immune tolerance, active operational immune tolerance and induced immune tolerance. Multiple clinical trials have confirmed the safety and feasibility of these approaches. Compared with adults, pediatric recipients undergoing liver transplantation have better potential of immune tolerance, especially the living donor liver transplant recipients. Nevertheless, it remains a challenge to predict whether a certain individual may achieve immune tolerance. In this article, research progresses on the characteristics of immune tolerance in pediatric recipients, induction of immune tolerance, operational immune tolerance, induced immune tolerance, screening of recipients and tolerance markers were reviewed, aiming to provide reference for the formulation of postoperative immunosuppressant regimens, reduce the overall exposure to immunosuppressants and lower the risk of adverse reactions induced by immunosuppressants in children undergoing liver transplantation.

     

    • FullText(HTML)
  • loading
    • References(70)
  • [1]
    中华医学会器官移植学分会. 中国儿童肝移植操作规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(3): 181-186. DOI: 10.3877/cma.j.issn.1674-3903.2019.03.005.

    Branch of Organ Transplantation of Chinese Medical Association. Technical operation specification for pediatric liver transplantation in China (2019 edition)[J/CD]. Chin J Transplant (Electr Edit), 2019, 13(3): 181-186. DOI: 10.3877/cma.j.issn.1674-3903.2019.03.005.
    [2]
    SPINNER JA, DENFIELD SW. Immunosuppressant drugs and their effects on children undergoing solid organ transplant[J]. Pediatr Rev, 2022, 43(2): 71-86. DOI: 10.1542/pir.2020-000620.
    [3]
    杨扬, 邓宜南. 肝细胞癌肝移植术后免疫抑制剂的应用[J]. 临床肝胆病杂志, 2021, 37(2): 263-266. DOI: 10.3969/j.issn.1001-5256.2021.02.005.

    YANG Y, DENG YN. Application of immunosuppressants after liver transplantation for hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(2): 263-266. DOI: 10.3969/j.issn.1001-5256.2021.02.005.
    [4]
    中华医学会器官移植学分会. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specifcation for clinical application of immunosuppressive agents in organ transplantation (2019 edition)[J]. Organ Transplant, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.
    [5]
    KOVAC D, CHOE J, LIU E, et al. Immunosuppression considerations in simultaneous organ transplant[J]. Pharmacotherapy, 2021, 41(1): 59-76. DOI: 10.1002/phar.2495.
    [6]
    ÅBERG F, ISONIEMI H, PUKKALA E, et al. Cancer after liver transplantation in children and young adults: a population-based study from 4 Nordic countries[J]. Liver Transpl, 2018, 24(9): 1252-1259. DOI: 10.1002/lt.25305.
    [7]
    PARMAR A, VANDRIEL SM, NG VL. Health-related quality of life after pediatric liver transplantation: a systematic review[J]. Liver Transpl, 2017, 23(3): 361-374. DOI: 10.1002/lt.24696.
    [8]
    PHAM YH, MILOH T. Liver transplantation in children[J]. Clin Liver Dis, 2018, 22(4): 807-821. DOI: 10.1016/j.cld.2018.06.004.
    [9]
    HOEGY D, BLEYZAC N, ROBINSON P, et al. Medication adherence in pediatric transplantation and assessment methods: a systematic review[J]. Patient Prefer Adherence, 2019, 13: 705-719. DOI: 10.2147/PPA.S200209.
    [10]
    KELLY D, WRAY J. Non-adherence and transition clinics[J]. Best Pract Res Clin Gastroenterol, 2020, 46/47: 101687. DOI: 10.1016/j.bpg.2020.101687.
    [11]
    王凯, 高伟. 儿童肝移植免疫耐受相关进展[J]. 临床肝胆病杂志, 2019, 35(11): 2402-2407. DOI: 10.3969/j.issn.1001-5256.2019.11.005.

    WANG K, GAO W. Research advances in immune tolerance in children receiving liver transplantation[J]. J Clin Hepatol, 2019, 35(11): 2402-2407. DOI: 10.3969/j.issn.1001-5256.2019.11.005.
    [12]
    CVETKOVSKI F, HEXHAM JM, BERGLUND E. Strategies for liver transplantation tolerance[J]. Int J Mol Sci, 2021, 22(5): 2253. DOI: 10.3390/ijms22052253.
    [13]
    MCCAUGHAN GW, BOWEN DG, BERTOLINO PJ. Induction phase of spontaneous liver transplant tolerance[J]. Front Immunol, 2020, 11: 1908. DOI: 10.3389/fimmu.2020.01908.
    [14]
    REYES J, ZEEVI A, RAMOS H, et al. Frequent achievement of a drug-free state after orthotopic liver transplantation[J]. Transplant Proc, 1993, 25(6): 3315-3319.
    [15]
    NI X, WANG Q, GU J, et al. Clinical and basic research progress on treg-induced immune tolerance in liver transplantation[J]. Front Immunol, 2021, 12: 535012. DOI: 10.3389/fimmu.2021.535012.
    [16]
    APPENZELLER-HERZOG C, HARTLEIF S, VIONNET J. Clinical parameters and biomarkers predicting spontaneous operational tolerance after liver transplantation: a scoping review[J]. Am J Transplant, 2021, 21(10): 3312-3323. DOI: 10.1111/ajt.16585.
    [17]
    STOLP J, ZAITSU M, WOOD KJ. Immune tolerance and rejection in organ transplantation[J]. Methods Mol Biol, 2019, 1899: 159-180. DOI: 10.1007/978-1-4939-8938-6_12.
    [18]
    VIONNET J, SÁNCHEZ-FUEYO A. Biomarkers of immune tolerance in liver transplantation[J]. Hum Immunol, 2018, 79(5): 388-394. DOI: 10.1016/j.humimm.2018.02.010.
    [19]
    WAN P, XU D, ZHANG J, et al. Liver transplantation for biliary atresia: a nationwide investigation from 1996 to 2013 in mainland China[J]. Pediatr Transplant, 2016, 20(8): 1051-1059. DOI: 10.1111/petr.12750.
    [20]
    SCHREIBER RA, HARPAVAT S, HULSCHER JBF, et al. Biliary atresia in 2021: epidemiology, screening and public policy[J]. J Clin Med, 2022, 11(4): 999. DOI: 10.3390/jcm11040999.
    [21]
    VIJ M, RELA M. Biliary atresia: pathology, etiology and pathogenesis[j]. Future Sci OA, 2020, 6(5): FSO466. DOI: 10.2144/fsoa-2019-0153.
    [22]
    常青锋, 王静, 宋翠萍. 活体肝移植治疗胆道闭锁儿童临床疗效研究[J]. 实用肝脏病杂志, 2021, 24(3): 431-434. DOI: 10.3969/j.issn.1672-5069.2021.03.032.

    CHANG QF, WANG J, SONG CP. Clinical efficacy of living donor liver transplantation for treatment of children with biliary atresia[J]. J Pract Hepatol, 2021, 24(3): 431-434. DOI: 10.3969/j.issn.1672-5069.2021.03.032.
    [23]
    高伟, 王凯, 马楠, 等. 亲属活体肝移植治疗儿童胆道闭锁306例临床分析[J]. 中华器官移植杂志, 2019, 40(1): 13-17. DOI: 10.3760/cma.j.issn.0254-1785.2019.01.004.

    GAO W, WANG K, MA N, et al. Living donor liver transplantations for pediatric patients with biliary atresia in a single center: 306[J]. Chin J Organ Transplant, 2019, 40(1): 13-17. DOI: 10.3760/cma.j.issn.0254-1785.2019.01.004.
    [24]
    FENG S, DEMETRIS AJ, SPAIN KM, et al. Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R[J]. Hepatology, 2017, 65(2): 647-660. DOI: 10.1002/hep.28681.
    [25]
    FENG S, EKONG UD, LOBRITTO SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants[J]. JAMA, 2012, 307(3): 283-293. DOI: 10.1001/jama.2011.2014.
    [26]
    FENG S, BUCUVALAS JC, MAZARIEGOS GV, et al. Efficacy and safety of immunosuppression withdrawal in pediatric liver transplant recipients: moving toward personalized management[J]. Hepatology, 2021, 73(5): 1985-2004. DOI: 10.1002/hep.31520.
    [27]
    YOSHITOMI M, KOSHIBA T, HAGA H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation[J]. Transplantation, 2009, 87(4): 606-614. DOI: 10.1097/TP.0b013e318195a7cb.
    [28]
    CASIRAGHI F, PERICO N, REMUZZI G. Mesenchymal stromal cells for tolerance induction in organ transplantation[J]. Hum Immunol, 2018, 79(5): 304-313. DOI: 10.1016/j.humimm.2017.12.008.
    [29]
    LU J, LI P, DU X, et al. Regulatory T cells induce transplant immune tolerance[J]. Transpl Immunol, 2021, 67: 101411. DOI: 10.1016/j.trim.2021.101411.
    [30]
    TRAN L, HUMAR A. Tolerance studies in liver transplantation: are we fooling ourselves?[J]. Curr Opin Organ Transplant, 2020, 25(2): 151-157. DOI: 10.1097/MOT.0000000000000738.
    [31]
    TODO S, YAMASHITA K, GOTO R, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation[J]. Hepatology, 2016, 64(2): 632-643. DOI: 10.1002/hep.28459.
    [32]
    LI J, THOMSON AW, ROGERS NM. Myeloid and mesenchymal stem cell therapies for solid organ transplant tolerance[J]. Transplantation, 2021, 105(12): e303-e321. DOI: 10.1097/TP.0000000000003765.
    [33]
    DAI H, ZHENG Y, THOMSON AW, et al. Transplant tolerance induction: insights from the liver[J]. Front Immunol, 2020, 11: 1044. DOI: 10.3389/fimmu.2020.01044.
    [34]
    YOU Y, WEN DG, GONG JP, et al. Research status of mesenchymal stem cells in liver transplantation[J]. Cell Transplant, 2019, 28(12): 1490-1506. DOI: 10.1177/0963689719874786.
    [35]
    THOMSON AW, HUMAR A, LAKKIS FG, et al. Regulatory dendritic cells for promotion of liver transplant operational tolerance: rationale for a clinical trial and accompanying mechanistic studies[J]. Hum Immunol, 2018, 79(5): 314-321. DOI: 10.1016/j.humimm.2017.10.017.
    [36]
    DU X, CHANG S, GUO W, et al. Progress in liver transplant tolerance and tolerance-inducing cellular therapies[J]. Front Immunol, 2020, 11: 1326. DOI: 10.3389/fimmu.2020.01326.
    [37]
    WANG P, JIANG Z, WANG C, et al. Immune tolerance induction using cell-based strategies in liver transplantation: clinical perspectives[J]. Front Immunol, 2020, 11: 1723. DOI: 10.3389/fimmu.2020.01723.
    [38]
    JIANG Y, QUE W, ZHU P, et al. The role of diverse liver cells in liver transplantation tolerance[J]. Front Immunol, 2020, 11: 1203. DOI: 10.3389/fimmu.2020.01203.
    [39]
    OWEN A, NEWSOME PN. Mesenchymal stromal cells, a new player in reducing complications from liver transplantation?[J]. Front Immunol, 2020, 11: 1306. DOI: 10.3389/fimmu.2020.01306.
    [40]
    JOHNSTONE BH, MESSNER F, BRANDACHER G, et al. A large-scale bank of organ donor bone marrow and matched mesenchymal stem cells for promoting immunomodulation and transplant tolerance[J]. Front Immunol, 2021, 12: 622604. DOI: 10.3389/fimmu.2021.622604.
    [41]
    MAZARIEGOS GV, REYES J, MARINO I, et al. Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up[J]. Transplant Proc, 1997, 29(1/2): 1174-1177. DOI: 10.1016/s0041-1345(96)00535-0.
    [42]
    DEVLIN J, DOHERTY D, THOMSON L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation[J]. Hepatology, 1998, 27(4): 926-933. DOI: 10.1002/hep.510270406.
    [43]
    TAKATSUKI M, UEMOTO S, INOMATA Y, et al. Weaning of immunosuppression in living donor liver transplant recipients[J]. Transplantation, 2001, 72(3): 449-454. DOI: 10.1097/00007890-200108150-00016.
    [44]
    OIKE F, YOKOI A, NISHIMURA E, et al. Complete withdrawal of immunosuppression in living donor liver transplantation[J]. Transplant Proc, 2002, 34(5): 1521. DOI: 10.1016/s0041-1345(02)02980-9.
    [45]
    EASON JD, COHEN AJ, NAIR S, et al. Tolerance: is it worth the risk?[J]. Transplantation, 2005, 79(9): 1157-1159. DOI: 10.1097/01.tp.0000162084.46555.10.
    [46]
    TRYPHONOPOULOS P, TZAKIS AG, WEPPLER D, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation[J]. Am J Transplant, 2005, 5(3): 608-613. DOI: 10.1111/j.1600-6143.2004.00743.x.
    [47]
    TRYPHONOPOULOS P, RUIZ P, WEPPLER D, et al. Long-term follow-up of 23 operational tolerant liver transplant recipients[J]. Transplantation, 2010, 90(12): 1556-1561. DOI: 10.1097/TP.0b013e3182003db7.
    [48]
    TISONE G, ORLANDO G, CARDILLO A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence[J]. J Hepatol, 2006, 44(4): 702-709. DOI: 10.1016/j.jhep.2005.11.047.
    [49]
    ORLANDO G, MANZIA T, BAIOCCHI L, et al. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months[J]. Transpl Immunol, 2008, 20(1/2): 43-47. DOI: 10.1016/j.trim.2008.08.007.
    [50]
    ASSY N, ADAMS PC, MYERS P, et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid[J]. Transplantation, 2007, 83(12): 1571-1576. DOI: 10.1097/01.tp.0000266678.32250.76.
    [51]
    PONS JA, RAMÍREZ P, REVILLA-NUIN B, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients[J]. Clin Transplant, 2009, 23(3): 329-336. DOI: 10.1111/j.1399-0012.2008.00944.x.
    [52]
    DE LA GARZA RG, SAROBE P, MERINO J, et al. Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance[J]. Liver Transpl, 2013, 19(9): 937-944. DOI: 10.1002/lt.23686.
    [53]
    LIN NC, WANG HK, YEH YC, et al. Minimization or withdrawal of immunosuppressants in pediatric liver transplant recipients[J]. J Pediatr Surg, 2015, 50(12): 2128-2133. DOI: 10.1016/j.jpedsurg.2015.08.043.
    [54]
    LEVITSKY J, BURRELL BE, KANAPARTHI S, et al. Immunosuppression withdrawal in liver transplant recipients on sirolimus[J]. Hepatology, 2020, 72(2): 569-583. DOI: 10.1002/hep.31036.
    [55]
    BENÍTEZ C, LONDOÑO MC, MIQUEL R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients[J]. Hepatology, 2013, 58(5): 1824-1835. DOI: 10.1002/hep.26426.
    [56]
    JUCAUD V, SHAKED A, DESMARAIS M, et al. Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients[J]. Hepatology, 2019, 69(3): 1273-1286. DOI: 10.1002/hep.30281.
    [57]
    SHAKED A, DESMARAIS MR, KOPETSKIE H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation[J]. Am J Transplant, 2019, 19(5): 1397-1409. DOI: 10.1111/ajt.15205.
    [58]
    POPP FC, FILLENBERG B, EGGENHOFER E, et al. Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)[J]. J Transl Med, 2011, 9: 124. DOI: 10.1186/1479-5876-9-124.
    [59]
    DETRY O, VANDERMEULEN M, DELBOUILLE MH, et al. Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase Ⅰ-Ⅱ, open-label, clinical study[J]. J Hepatol, 2017, 67(1): 47-55. DOI: 10.1016/j.jhep.2017.03.001.
    [60]
    ZHANG YC, LIU W, FU BS, et al. Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation[J]. Cytotherapy, 2017, 19(2): 194-199. DOI: 10.1016/j.jcyt.2016.11.005.
    [61]
    SOEDER Y, LOSS M, JOHNSON CL, et al. First-in-human case study: multipotent adult progenitor cells for immunomodulation after liver transplantation[J]. Stem Cells Transl Med, 2015, 4(8): 899-904. DOI: 10.5966/sctm.2015-0002.
    [62]
    SHI M, LIU Z, WANG Y, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection[J]. Stem Cells Transl Med, 2017, 6(12): 2053-2061. DOI: 10.1002/sctm.17-0134.
    [63]
    ClinicalTrials. gov[EB/OL]. [2022-01-15]. https://clinicaltrials.gov/.
    [64]
    LI M, ZHAO W, WANG Y, et al. A wave of Foxp3+ regulatory T cell accumulation in the neonatal liver plays unique roles in maintaining self-tolerance[J]. Cell Mol Immunol, 2020, 17(5): 507-518. DOI: 10.1038/s41423-019-0246-9.
    [65]
    HALMA J, PIERCE S, MCLENNAN R, et al. Natural killer cells in liver transplantation: can we harness the power of the immune checkpoint to promote tolerance?[J]. Clin Transl Sci, 2021, DOI: 10.1111/cts.13208[Epub ahead of print].
    [66]
    WANG K, SONG ZL, WU B, et al. Different phenotypes of CD4+CD25+Foxp3+ regulatory T cells in recipients post liver transplantation[J]. Int Immunopharmacol, 2019, 69: 194-201. DOI: 10.1016/j.intimp.2019.01.048.
    [67]
    MARTÍNEZ-LLORDELLA M, LOZANO JJ, PUIG-PEY I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients[J]. J Clin Invest, 2008, 118(8): 2845-2857. DOI: 10.1172/JCI35342.
    [68]
    LAU AH, VITALONE MJ, HAAS K, et al. Mass cytometry reveals a distinct immunoprofile of operational tolerance in pediatric liver transplantation[J]. Pediatr Transplant, 2016, 20(8): 1072-1080. DOI: 10.1111/petr.12795.
    [69]
    LI Y, KOSHIBA T, YOSHIZAWA A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation[J]. Am J Transplant, 2004, 4(12): 2118-2125. DOI: 10.1111/j.1600-6143.2004.00611.x.
    [70]
    BOHNE F, MARTÍNEZ-LLORDELLA M, LOZANO JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation[J]. J Clin Invest, 2012, 122(1): 368-382. DOI: 10.1172/JCI59411.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (377) PDF downloads(119) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return